World Orphan Drug Congress
As regulatory expectations evolve and rare disease therapies become more complex, life sciences organizations are under increasing pressure to accelerate innovation while maintaining compliance, quality, and data integrity.
REGISTER HERE: https://www.terrapinn.com/conference/world-orphan-drug-congress-usa/index.stm
That’s why Novatek International is excited to announce that Vicky Azadian will be attending the World Orphan Drug Congress USA 2026, taking place June 9–11, 2026 at the Thomas M. Menino Convention & Exhibition Center in Boston, MA. The event brings together global leaders across pharma, biotech, regulatory agencies, patient advocacy groups, and technology providers focused on advancing rare disease and orphan drug development.
Key discussions will explore AI, digital health, regulatory strategy, advanced therapies manufacturing, patient data, and scalable clinical and manufacturing operations — all critical areas for organizations navigating increasing compliance demands and operational risk.
Novatek International helps pharmaceutical manufacturers modernize validation, strengthen audit readiness, improve data integrity, and streamline GxP workflows through connected digital quality and manufacturing solutions.
🔹 Learn more or register for the event: World Orphan Drug Congress USA 2026
🔹 Visit Novatek International to discover how digital transformation can reduce validation effort, improve compliance readiness, and support more efficient pharmaceutical manufacturing operations.
#PharmaManufacturing #RareDisease #GxP #QualityAssurance #DigitalTransformation
What do you see as the biggest operational challenge facing rare disease and orphan drug manufacturers today?